Europe Cancer Biomarkers Market Overview:
The Europe cancer biomarker
market was valued at USD 3,076 million in 2018 and is expected to grow at a
CAGR of 11% for the years 2018-2025 to reach USD 6,407 million. The
technological progress in research and developmental activities has progressed
the high growth of the cancer biomarker market in Europe.
Biomarkers are used in single
or in combination to identify the health or disease of the individual. They are
used to measure biological states such as blood pressure, cholesterol level and
monitor and forecast the health level of the individual. Different varieties of biomarkers are applied
currently for various applications. Each biological system consists of its
personal biomarkers.
Browse details of 150
number of pages research report developed on Europe Cancer Biomarkers Market
Research Report @ https://www.researchcosmos.com/reports/europe-cancer-biomarkers-market/1272884094
Drivers, Challenges, and Opportunities:
The foremost driving factors
for the biomarkers market in Europe is an increase in the number of low costs
for conducting clinical trials in its countries. The performance of biomarkers
in the diagnostic process is growing rapidly due to its more accurate results.
These biomarkers also have some limitations such as the technical issues
related to sample and storage. The experiment cost of biomarkers is large. It
includes high expense but relatively low cost and benefit rate.
The European market has a
huge opportunity to grow in personalized medication on account of the support
generated for the biomarkers test, and the growing number of cancer patients in
the region. Moreover, the various market segments and sub-segments with respect
to biomarkers are proving to be quite profitable for the market growth during
the forecast period. Additionally, the lack of acceptance of the cancer biomarker
from the general populace, unfavorable compensation and the shortage of skilled
personnel maybe some of the major challenges faced by the market in the region.
Ask Free Sample of
the Report @ https://www.researchcosmos.com/request/europe-cancer-biomarkers-market/1272884094
Geographic Segmentation:
Europe cancer biomarker
market is witnessing significant growth due to technological developments. It includes
the regions of Germany, Spain, United Kingdom, Italy, France and the rest of
Europe. The growing number of cancer cases and the encouragement by the government
for biomarker research and development are aiding the growth for the European
market. Some of the associations supporting the market in Europe are European
Association for Cancer Research, German Consortium for Translational Cancer
Research and European Society for Breast Cancer Specialist.
Key Players:
Few of the leading players in
the market are Agendia N.V., Becton Dickinson and Company, Qiagen N.V.,
Diadexus Inc., Aureon Biosciences, Inc., Agilent Technologies, Inc., Clarient,
Inc., Astellas Pharma Inc., Beckman Coulter, Sanofi, Bristol-Myers Squibb,
Abbott Laboratories, Roche Diagnostics Ltd., Illumina, Inc. and Celgene
Corporation.
For any queries,
inquire more @ https://www.researchcosmos.com/discount/europe-cancer-biomarkers-market/1272884094
About Us:
Research Cosmos is a provider of standard and customized
Industry research, business intelligence and consulting services across more
than 100 domains in different industries of the world. We host the trending
Industry reports of the world’s top-notch publishing companies, offering
services to a wide range of customers from students to fortune 500 companies
and discloses the hidden opportunities in every leading industry of the world.
Contact:
Kevin Stewart
kevin@researchcosmos.com
Global Sales Manager
Research Cosmos
+1 888 709 8757
No comments:
Post a Comment